Inhibrx Biosciences, Inc. Income Statement
INBX / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Inhibrx Biosciences, Inc. reported $1M in revenue and $140M in net loss for FY2025. Revenue has declined at a 15.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.3M | $1.8M | $1.8M |
| SG&A Expense | $23.3M | $29.4M | $29.4M |
| R&D Expense | $113.0M | $191.6M | $191.6M |
| Operating Income | -$135.0M | -$219.2M | -$219.2M |
| Income Tax | $2.0K | $3.0K | $3.0K |
| Net Income | -$140.1M | -$241.4M | -$241.4M |
| EPS (Basic) | -$9.04 | -$20.48 | -$20.48 |
| EPS (Diluted) | -$9.04 | -$20.48 | -$20.48 |
| Shares Outstanding | 14.6M | 47.4M | 11.8M |
| Operating Margin | -10386.5% | -12178.9% | - |
| Profit Margin | -10773.5% | -13408.9% | - |